GS-5806

DRUG3 trials

Sponsors

Gilead Sciences

Conditions

RSV InfectionRespiratory Syncytial Virus Infections

Phase 1

Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)

WithdrawnNCT01797419

Gilead SciencesRespiratory Syncytial Virus Infections

Start: 2013-05-31End: 2013-08-31Updated: 2013-10-28

A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806

CompletedNCT01801293

Gilead SciencesRSV Infection

Start: 2013-03-31End: 2013-04-30Updated: 2013-06-10

Phase 2

Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)

CompletedNCT01756482

Gilead SciencesRespiratory Syncytial Virus Infections

Start: 2012-11-30End: 2013-06-30Updated: 2015-08-21

Related Papers

Use of qualitative integrative cycler PCR (qicPCR) to identify optimal therapeutic dosing time-points in a Respiratory Syncytial Virus Human Viral Challenge Model (hVCM).

2015-08-315 citations

Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study

New England Journal of Medicine2014-08-20334 citations